Item 8.01 Other Events.
On December 8, 2020, Syros Pharmaceuticals, Inc., a Delaware corporation (the
"Company"), issued a press release announcing the closing of a previously
announced private placement of an aggregate of 10,312,500 shares of the
Company's common stock, par value $0.001 per share (the "Shares"), and, in lieu
of Shares, pre-funded warrants (the "Pre-Funded Warrants") to purchase an
aggregate of 1,000,000 shares of common stock, and, in each case, accompanying
warrants (the "Warrants") to purchase an aggregate of up to 2,828,125 additional
shares of common stock (or Pre-Funded Warrants to purchase common stock in lieu
thereof) at a price of $8.00 per share and accompanying Warrant (or $7.99 per
Pre-Funded Warrant and accompanying Warrant). The private placement resulted in
gross proceeds of approximately $90.5 million, before deducting estimated
offering expenses payable by the Company. The full text of the press release
issued in connection with this announcement is attached as Exhibit 99.1 to this
Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
Exhibit
No. Description
99.1 Press Release, dated December 8, 2020
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses